Highlights d Human pDCs and cDC2s secrete a different set of chemokines upon activation d Activated human pDCs attract CD8 + T cells, CD56 + T cells, and gd T cells in vitro d cDC2-and pDC-based cancer vaccines attract lymphocytes in melanoma patient skin SUMMARY Plasmacytoid dendritic cells (pDCs) and type 2 conventional dendritic cells (cDC2s) are currently under evaluation for use in cancer vaccines. Although both DC subsets can activate adaptive and innate lymphocytes, their capacity to recruit such cells is rarely considered. Here, we show that pDCs and cDC2s display a striking difference in chemokine secretion, which correlates with the recruitment of distinct types of immune effector cells. Activated pDCs express high levels of CXCR3 ligands and attract more CD8 + T cells, CD56 + T cells, and gd T cells in vitro, compared to cDC2s. Skin from melanoma patients shows an influx of immune effector cells following intradermal vaccination with pDCs or cDC2s, with pDCs inducing the strongest influx of lymphocytes known to possess cytolytic activity. These findings suggest that combining both DC subsets could unite the preferred chemoattractive properties of pDCs with the superior T cell priming properties of cDC2s to ultimately enhance vaccine efficacy.
In Brief
Human plasmacytoid dendritic cells and type 2 conventional dendritic cells are currently used in cancer vaccines to induce antitumor immune responses. van Beek et al. compared their chemoattractive properties and identified a striking difference in chemokine secretion, resulting in the attraction of distinct immune effector cells.
INTRODUCTION
Dendritic cells (DCs) are highly specialized in the uptake, processing, and presentation of antigens. Upon maturation induced by pathogen-associated molecular patterns that are present during infection, DCs move from the periphery to the draining lymph node, where they activate antigen-specific T cells to initiate an adaptive immune response (Banchereau and Steinman, 1998) . These capacities are exploited in DC-based cancer vaccines. In this type of immunotherapy, patient-derived DCs are stimulated and loaded with antigen ex vivo before being injected back into the patient. This approach has shown both immunological and clinical responses in immunogenic cancers such as melanoma (Palucka and Banchereau, 2012) . The most common type of DCs used for this purpose are generated from monocytes (moDCs). However, in recent years, the use of primary DC subsets isolated directly from peripheral blood has become a promising alternative, offering several advantages over the use of moDCs, such as less-extensive ex vivo culture periods (Wimmers et al., 2014) .
At least three subsets of primary DCs can be identified in human peripheral blood: plasmacytoid DCs (pDCs), CD141 (BDCA3)-expressing conventional DCs (relabeled as cDC1s), and CD1c (BDCA1)-expressing conventional DCs (relabeled as cDC2s) (Collin and Bigley, 2018) . To date, the two most abundant primary subsets-pDCs and cDC2s-have been tested in clinical trials. The first phase I/II pDC vaccination study in melanoma patients utilized pDCs stimulated with Fr€ uhsommer meningoencephalitis (FSME) prophylactic vaccine for thickborne encephalitis (Tel et al., 2013) . cDC2s were subsequently tested as a cancer vaccine and were stimulated with granulocyte-macrophage colony-stimulating factor (GM-CSF) (Schreibelt et al., 2016) . Since pre-clinical data indicate that a combination of DC subsets might further improve vaccine efficacy (van Beek et al., 2016) , our most recent clinical trials use protamine-RNA (pRNA) complexes to stimulate DCs (Bol et al., 2019) . This clinical grade Toll-like receptor 7/8 agonist has been shown to induce strong maturation of both DC subsets as well as when pDCs and cDC2s are cultured together (Skö ld et al., 2015) .
Upon maturation, DCs increase their surface expression of costimulatory molecules and release cytokines, with which they can stimulate adaptive and innate immune cells. Most DC vaccination studies focus on the induction of antigen-specific adaptive immune cells, particularly CD8 + T cells and T helper 1 (Th1)-polarized CD4 + T cells (Aarntzen et al., 2013) . Besides these prototypical immune effector cells, it is becoming more recognized that DC crosstalk with innate and innate-like immune cells may play an important role in cancer immunotherapy (van Beek et al., 2014) . However, a prerequisite for all of these interactions to take place in vivo is that DCs and immune effector cells meet. In this context, the migratory capacity of DCs is well characterized (Worbs et al., 2017) , but the ability of DCs to recruit other immune cells is often underappreciated.
Here, we characterized the repertoire of chemokines produced by pDCs and cDC2s upon stimulation with the aforementioned clinical grade stimuli. Furthermore, we compared pDCs to cDC2s in their ability to attract immune cells in vitro. Finally, we studied the chemoattractive properties of pDC and cDC2 vaccines in vivo by analyzing patient-derived delayed-type hypersensitivity (DTH) skin biopsies. Our data demonstrate a different chemokine expression profile for pDCs and cDC2s that results in the recruitment of distinct types of immune effector cells.
RESULTS

pDCs and cDC2s Differentially Express Chemokine Genes
Chemokines are crucial regulators of immune cell migration. To investigate differences in chemokine production between pDCs and cDC2s, we first analyzed gene expression data of DC subsets using our dataset previously deposited at the GEO (Mathan et al., 2017) . pDCs were stimulated with FSME or pRNA, while cDC2s were stimulated with GM-CSF or pRNA, stimuli used previously in DC vaccination trials. Hierarchical clustering shows that chemokine gene expression differs per DC subset and per DC activation status ( Figure 1 ). Inflammatory chemokines CCL2, CCL3, and CCL4 were highly expressed by both activated pDCs and cDC2s. However, pDCs expressed higher levels of CXCL9, CXCL10, and CXCL11 than cDC2s. The chemokines encoded by these genes are all ligands for chemokine (C-X-C motif) receptor 3 (CXCR3). In addition, pDCs exhibited high read counts for CXCL8, although lower than those of activated cDC2s.
Activated cDC2s selectively expressed a large set of chemokines: the CXCR1/CXCR2 ligands CXCL1, CXCL2, CXCL3, CXCL5, CXCL7, and CXCL8; chemokine (C-C motif) receptor 4 (CCR4) ligands CCL17 and CCL22; and CCL1, CCL20, CCL24, and CXCL16. Of these, CCL1, CCL17, CCL22, and CCL24 are associated with a Th2-type of immune response (Sallusto et al., 1998; Soler et al., 2006) , while CCL20 attracts Th17 cells (Kryczek et al., 2008) . Interestingly, CXCL16 was also highly expressed in non-stimulated cDC2s. The type of DC and the presence of a maturation stimulus mainly determined the chemokine expression profile. To a lesser extent, the specific type of stimulus affected chemokine expression by primary DCs. This was especially evident for GM-CSF versus pRNA: CCL17, CXCL5, and CXCL7 expression was higher in GM-CSF-stimulated cDC2s. Conversely, CCL2, CCL5, CCL19, and CCL20 expression was higher in pRNA-stimulated cDC2s. The latter three chemokines were also expressed by pRNA-activated pDCs. Taken together, DC subsets differentially express chemokine genes, with activated pDCs exhibiting a high expression of genes encoding CXCR3 ligands and activated cDC2s exhibiting a selective expression of genes encoding CXCR1/CXCR2 ligands and Th2-and Th17-associated chemokines.
Chemokine Gene Expression by pDCs and cDC2s Reflects Secreted Protein Levels
In order to validate chemokine expression by DC subsets on a protein level, we measured six highly expressed chemokines in a DC-conditioned medium by Luminex assay. In accordance with gene expression data, CXCL2 and CXCL5 were preferentially secreted by activated cDC2s (Figures 2A and 2B ), whereas CXCL8 was strongly secreted by both subsets and with the highest values for cDC2s ( Figure 2C ). Activated pDCs secreted substantial amounts of CXCL10, which was also consistent with gene expression ( Figure 2D ). However, the stimulation of pDCs with pRNA resulted in a much stronger secretion of this chemokine than did the stimulation with FSME, a difference that was not observed on the RNA level. Surprisingly, while the gene expression of CXCL10 was low in cDC2s, a high secretion of this chemokine was measured on the protein level for cDC2s stimulated with pRNA. CCL4 secretion, on the other hand, closely resembled the gene expression pattern, with clear production by both DC subsets upon activation ( Figure 2E ). Finally, CCL22 was secreted by cDC2s but not by pDCs, a pattern similar to that of the RNA sequencing dataset ( Figure 2F ). Taken together, chemokine expression by human primary DCs at the RNA level generally reflects the secretion at the protein level.
Activated pDCs Attract Cytolytic Immune Effector Cells
In Vitro Next, we performed migration assays in vitro to determine which types of immune effector cells could be attracted by the chemokines secreted by human DC subsets. The DC-conditioned 
Figure 2. Chemokine Protein Expression of pDCs and cDC2s Follows Chemokine Gene Expression Patterns
Gene expression data were generated by RNA sequencing of pDCs and cDC2s cultured overnight with indicated stimuli. Protein expression of (A) CXCL2, (B) CXCL5, (C) CXCL8, (D) CXCL10, (E) CCL4, and (F) CCL22 levels in supernatants of overnight stimulated pDCs and cDC2s was determined by Luminex assay. Black bars, pDCs; white bars, cDC2s. Data are represented as mean ± SEM with n = 3 for RNA expression and n = 7 for protein expression. medium of overnight cultures was used in a transwell assay to attract peripheral blood mononuclear cells (PBMCs). Migrated PBMCs were phenotyped and quantified by flow cytometry (Figure S1 ). The medium conditioned by pRNA-stimulated pDCs robustly attracted CD8 + ab T cells, CD56 + T cells, and gd T cells ( Figure 3A) . In contrast, the cDC2-conditioned medium did not recognizably attract CD8 + T cells, even when using stimulated cDC2s ( Figure 3B ). When activated by pRNA, cDC2s did induce a modest migration of CD56 + T cells and gd T cells. The medium conditioned by co-cultures of pDCs and cDC2s induced a similar attraction of cytolytic immune effector cells as the medium conditioned by pRNA-stimulated pDCs alone, even though the co-cultures contained 50% fewer pDCs ( Figure 3C ). The medium conditioned by pDCs or cDC2s furthermore showed an increased natural killer (NK) cell recruitment, with pRNA-stimulated cDC2s reaching statistical significance (Figures S2A and DCs were cultured for 18 h with indicated stimuli (A and B) or pRNA (C). The conditioned medium from these DC cultures was used in a 5-mm pore size, 3-h transwell migration assay with PBMCs. Migrated cells were quantified using flow cytometry. Migration was calculated in fold increase as [number of migrated cells in condition] / [number of migrated cells in control], with the cell culture medium only serving as the negative control. Data are represented as mean ± SD with n = 7 or 8. Data points from pRNA conditions of pDC single cultures in (A) and of cDC2 cultures in (B) were also used in (C). Significance was determined by oneway ANOVA with Bonferroni correction (*p < 0.05; **p < 0.01; ***p < 0.001). Statistics depicted under the brackets represent differences in the migration of the respective condition compared to the negative control, while statistics depicted above the brackets represent differences in migration between indicated stimuli (A and B) or DC subsets (C). See also Figures S1-S4. S2B). For CD4 + ab T cells, B cells, and monocytes, our data did not show clear evidence for attraction by the pDC-conditioned medium. In contrast, unstimulated and pRNA-matured cDC2s induced the migration of monocytes, while co-cultures of pDCs and cDC2s in the presence of pRNA attracted NK cells and modestly attracted CD4 + ab T cells ( Figure S2C ). Furthermore, the monocyte attraction by pRNA-stimulated cDC2s was completely abrogated when both subsets were combined. In summary, these data provide evidence for the ability of pDCs to attract effector lymphocytes known to possess cytolytic activity and show that this ability is not hampered when pDCs are cocultured with cDC2s.
Since pRNA-stimulated pDCs expressed high levels of CXCL9, CXCL10, and CXCL11, we sought to determine if the migration of CD8 + ab T cells, CD56 + T cells, and gd T cells toward the pDC-conditioned medium was CXCR3 dependent. Indeed, pre-incubation with an anti-CXCR3 blocking antibody decreased the migration of these effector lymphocytes toward the medium conditioned by pRNA-stimulated pDCs ( Figure S3 ). cDC2s uniquely expressed Th2-and Th17-associated chemokines but did not strongly attract effector lymphocytes in the migration assays using bulk PBMCs. Since the frequency of Th2 and Th17 cells in bulk PBMCs can be low, we polarized naive CD4 + T cells in vitro to different Th cell subsets and used them in migration assays. Th2 and Th17 cells, but not Th1 cells, robustly migrated toward the cDC2-conditioned medium, while the opposite trend was seen for the pDC-conditioned medium (Figure S4) . These findings are consistent with the chemokine expression profile of pDCs and cDC2s.
Skin Injected with a Combined pDC/cDC2 Vaccine Can
Contain Populations of Innate(-like) Lymphocytes DTH skin tests have been shown to be a useful tool for monitoring immune responses induced by DC vaccines de Vries et al., 2005) . To this end, DCs loaded with tumor-associated peptides are injected intradermally into the back of the patient, and 48 h later, punch biopsies are taken. Part of the biopsies are cultured for up to 3 weeks in the presence of low-dose interleukin (IL)-2 to amplify the population of skin-infiltrating lymphocytes (SKILs). Such cultures are used to detect the presence of peptide-specific CD8 + and CD4 + T cells, which could be induced by the DC vaccine. However, the presence of innate(-like) lymphocytes such as NK cells, CD56 + T cells, and gd T cells is rarely monitored. We used SKIL cultures of our adjuvant clinical DC vaccination trial to determine if they contain innate(-like) lymphocytes. In total, we analyzed 148 SKIL cultures derived from 48 stage III melanoma patients receiving combined vaccination with pRNA-activated pDCs and cDC2s. Flow cytometric analysis demonstrated the presence of NK cells in the SKIL cultures of these patients ( Figure 4A) , with a frequency ranging from 0.6% to 31.2% (mean 5.5%) of viable SKILs. The majority of NK cells exhibited a CD56 bright CD16 À phenotype ( Figure 4B ), although CD56 bright CD16 + NK cells were occasionally present. CD56 + T cells were often either absent or present as a clear population, amounting to up to 37.5% of T cells (mean 2.2%). Detected CD56 + T cells were not of the invariant NK T cell subtype (data not shown). gd T cells were present in small numbers, constituting 0.1%-6.3% (mean 1.4%) of T cells. Vd1 + gd T cells, which form a major gd T cell population in skin, were frequently among them. Because of the long-term culture process, the composition of the SKIL populations may have changed over time. Nevertheless, the clear presence of NK cells, CD56 + T cells, and gd T cells in multiple SKIL cultures strongly suggests the presence of these cells in the original skin biopsies.
pDC and cDC2 Vaccines Attract Conventional and Innate(-like) Lymphocytes Following Intradermal Injection in Melanoma Patients
To determine if the number of conventional and innate(-like) lymphocytes present in the skin changes following the intradermal injection of primary DC subsets, we analyzed cryosections of DTH skin biopsies from previously conducted DC vaccination trials by multispectral imaging (Schreibelt et al., 2016; Tel et al., 2013) . Biopsies from three patients who received FSME-stimulated pDCs and biopsies from three patients who received GM-CSF-stimulated cDC2s were selected (Table 1) . From each patient, three biopsies were stained: two biopsies taken from a site injected with the DC vaccine and one control biopsy. Figure 5 compares pDC-injected skin to the control skin of one patient. The pDC-injected skin showed a clear presence of CD8 + T cells, CD8 À T cells, NK cells, CD56 + T cells, and gd T cells. Although these lymphocytes could be detected in the papillary dermal layer close to the epidermis ( Figure 5C ), most were present in agglomerations in the deeper reticular dermis ( Figure 5E ). Here, lymphocytes could be detected that were close to DCs, suggesting cellular interactions. In contrast, the control biopsy did not show obvious agglomerations of lymphocytes and (skin-resident) DCs in the dermal layer close to the epidermis ( Figure 5D ) or in the deeper reticular dermis (Figure 5F ). Next, we quantified the influx of lymphocytes for all selected patients. The analysis strategy is shown in Figures  6A-6D . Although several biopsies of skin injected with a DC vaccine contained a clear infiltration, others were-like the control biopsies-devoid of lymphocytes. This variance was also present when comparing two biopsies of the same patient (Figure S5) and might therefore reflect biological variations in in vivo immune cell attraction by DC vaccines and/or technical issues; we cannot exclude the possibility that the tissue section was cut from an area too far away from the injection site or that the injection was placed subcutaneously instead of intradermally. Nonetheless, and even though this cohort only contained a limited number of patients, the results suggest an increase in the infiltration of all measured lymphocyte subsets for both types of DC vaccines ( Figures 6E and 6F ). Finally, skin injected with FSME-stimulated pDCs was compared directly with skin injected with GM-CSF-stimulated cDC2s, as well as with control biopsies from both trials ( Figure 6G ). This comparison revealed a similar influx of CD8 À T cells in pDC-injected skin compared to cDC2-injected skin and a stronger influx of cytolytic lymphocytes-most notably CD8 + T cells-in skin injected with pDCs. This pattern resembles the migration patterns observed in our in vitro assays and highlights the potential of pDCs to recruit cytolytic immune effector cells during cancer immunotherapy.
DISCUSSION
DC-based vaccines utilizing primary DCs are emerging as a promising form of treatment for various types of cancer (Wimmers et al., 2014) . Both pDCs and cDC2s have been shown to induce T cell responses in melanoma patients (Schreibelt et al., 2016; Tel et al., 2013) . In addition, DCs possess the ability to interact with NK cells and unconventional T cells, which could further potentiate the antitumor immune response (van Beek et al., 2014) . The spatial convergence of DCs and immune effector cells in vivo is crucial for this crosstalk to take place. Here, we addressed the ability of human pDCs and cDC2s to attract immune effector cells in vitro and in vivo in vaccinated melanoma patients. Our data show a striking divergence in chemokine secretion by pDCs and cDC2s upon activation by clinical grade stimuli, which correlates with the recruitment of distinct types of immune effector cells.
We observed that pDCs produced high levels of CXCR3 and CCR5 ligands and attracted CD8 + T cells, NK cells, CD56 + T cells, and gd T cells in vitro and in vivo. These data correlate with high expression levels of CXCR3 and CCR5 by activated CD8 + T cells (Groom and Luster, 2011) , CD56 + T cells (Campbell et al., 2001) , and gd T cells (Glatzel et al., 2002) , and their capacity to migrate to the corresponding ligands. Indeed, blocking CXCR3 inhibited their migration toward activated pDCs. NK cells can be subdivided in a CD56 dim CD16 + subset, the dominant subset in blood that possesses strong cytolytic functions, and a CD56 bright CD16 À subset that predominates in secondary lymphoid organs and can secrete large amounts of cytokines. CD56 bright CD16 À NK cells express high levels of CXCR3 and CCR5 (Campbell et al., 2001) and are thus likely to be attracted by pDC-derived chemokines. Accordingly, we found that the majority of NK cells present in SKIL cultures derived from skin injected with a combined pDC/cDC2 vaccine were CD56 bright , of which most lacked expression of CD16. In addition, CD56 bright CD16 + cells were occasionally observed. This suggests an activation of attracted NK cells, as CD56 bright NK cells have been reported to acquire CD16 expression upon activation (Romagnani et al., 2007) . Our results corroborate with previous findings that virally stimulated human pDCs attract NK cells and activated T cells via secretion of CCL4 and CXCL10 (Megjugorac et al., 2004) . Furthermore, the pattern of immune effector cell recruitment by pDCs corresponds with the notion that moDCs secreting high levels of CCL4, CXCL9, CXCL10, and CXCL11 can attract CD8 + T cells, NK cells, CD56 + T cells, and gd T cells (Van Acker et al., 2017) . Overall, the type of immune effector cells that migrate toward activated pDCs fits the physiological function of pDCs. They play an essential role in combatting viral infections, for which a Th1 and cytotoxic response is preferred. A similar type of response is preferred in cancer immunotherapy (Kranz et al., 2016) .
cDC2s are involved in a multitude of immunological responses, including responses against viruses, bacteria, fungi, and parasites. Unsurprisingly, therefore, we find that cDC2s can express Th2-and Th17-associated chemokines, which corroborates with previous reports (Penna et al., 2002; Piqueras et al., 2006) . Moreover, we found that cDC2s attracted in vitro polarized Th2 and Th17 cells. Furthermore, cDC2s selectively expressed high levels of chemokines that bind to CXCR1 and CXCR2 and are known to be strong inducers of neutrophil migration (de Oliveira et al., 2016) . CXCR1 ligation also mediates the migration of CD56 dim CD16 + NK cells, while CXCR2 can play a role in the migration of monocytes (Soehnlein et al., 2013) . Consistent with this notion, cDC2s recruited NK cells and monocytes in our assays in vitro.
Importantly, the stimulus used to activate the DCs can also impact chemokine secretion. cDC2 stimulation with pRNA results in a higher gene expression of Th1-associated chemokines CXCL9, CXCL10, CXCL11, and CCL5, as well as the Th17-associated chemokine CCL20, and a lower expression of the Th2-associated chemokine CCL17, as compared to stimulation with GM-CSF. Likewise, at the protein level, CXCL10 was highly secreted by pRNA-activated cDC2s, whereas unstimulated or GM-CSF-treated cDC2s did not produce detectable levels. For pDCs, the chemokine expression profile induced by FSME and pRNA was very similar, probably because both signal via Toll-like receptors (Skö ld et al., 2015; de Vries et al., 2011) . However, the expression of several inflammatory chemokines at the RNA level and the production of CXCL10 at the protein level was higher in pRNA-activated pDCs. Collectively, the pattern of chemokine secretion and immune cell attraction induced by pRNA makes it the preferred clinical grade stimulus over GM-CSF and FSME for use in primary DC-based vaccines against cancer.
Multiplex immunohistochemistry (IHC) staining of skin biopsies from previous clinical studies showed that an intradermal injection of pDCs and cDC2s in melanoma patients leads to a strong increase in effector lymphocytes at the injection spot. Consistent with our in vitro data, the pDC vaccine appeared to induce the strongest infiltration of CD8 + T cells. Interestingly, the majority of infiltrated lymphocytes were CD3 + CD8 À and thus likely represent CD4 + T cells, although we cannot exclude the possibility that they are CD4 À CD8 À T cells. Such a strong attraction of CD8 À T cells was not evident in the in vitro migration experiments with bulk PBMCs. However, frequencies of specific CD4 + T cell phenotypes such as Th2 and Th17, which are efficiently attracted by cDC2s, are much lower in bulk. Furthermore, in vivo crosstalk of DCs or effector lymphocytes with other cells Only after in vitro re-stimulation might play a role, and a general inflammatory response could also contribute to the accumulation of CD8 À T cells at the injection spot. Although pDCs and cDC2s exhibit differences in effector function, both offer characteristics that make them suitable for application in cancer immunotherapy. Where pDCs can enhance the cytolytic activity of innate effector cells via the release of interferon (IFN)-a, cDC2s appear to be the most potent inducers of T cell responses and can increase IFN-g production by effector lymphocytes via the release of IL-12 (Nizzoli et al., 2013; Romagnani et al., 2005) . We add to this model of dichotomy by showing that pDCs are superior to cDC2s in attracting effector lymphocytes known to possess cytolytic potential. Yet, while DTH skin biopsies of the pDC clinical study showed the strongest influx of CD8 + T cells, the presence of tumor antigen-specific CD8 + T cells was only seen in DTH biopsies of the cDC2 clinical study (Table 1) . This underscores that the recruitment of immune effector cells via chemokines does not differentiate in antigen specificity.
Combining pDCs and cDC2s in a single vaccine is proposed to further enhance vaccine efficacy, because DC subset-spe- Multispectral images of skin from a stage IV melanoma patient (patient VI-A-06) receiving DC vaccination. pDCs were injected intradermally with FSME-stimulated pDCs for immunomonitoring purposes. Skin biopsies were taken from the injected sites 2 days later. Control biopsies were taken from untreated skin. Cryosections from the biopsies were stained by multiplex IHC with a panel of antibodies directed against CD3, CD8, CD56, TCRgd, and a DC marker (CD123 for pDC biopsies, human leukocyte antigen DR [HLA-DR] for control biopsies) and with DAPI nuclear staining. cific effector functions may be complementary (van Beek et al., 2016) . In line with this hypothesis, we report that co-cultures of pDCs and cDC2s significantly attract CD8 + T cells, CD56 + T cells, gd T cells, and NK cells in vitro and show a synergistic effect in the attraction of CD4 + T cells. Moreover, detection of CD56 + T cells, gd T cells, and NK cells in the SKIL cultures indicates that these innate(-like) effector cells are also present in vivo in the skin of melanoma patients injected with a combined pDC/cDC2 vaccine. Altogether, these data suggest that combining pDCs and cDC2s in a single vaccine could unite the strong Th1 type of chemoattractive properties of pDCs and the superior adaptive T cell priming properties of cDC2s.
An interesting prospect is the use of ex-vivo-stimulated DCs to attract immune effector cells to the tumor site. Hampered migration of effector T cells into the tumor represents one of the major obstacles for immunotherapies and is often associated with poor prognosis (Galon et al., 2006) . Increasing the level of inflammatory chemokines such as CXCL9, CXCL10, and CXCL11 at the tumor site could be a strategy to increase the recruitment of cytolytic effector cells. In murine melanoma models, CXCR3 was demonstrated to mediate the migration of CD8 + effector T cells into the tumor, thereby playing an important role in the effectiveness of anti-PD-1 treatment (Chheda et al., 2016; Mikucki et al., 2015) . Furthermore, an elevated expression of CXCL9 in melanoma tumor biopsies positively correlates with the patient response to anti-PD-L1 therapy (Herbst et al., 2014) . We therefore propose that injecting properly activated pDCs in or near the tumor lesion may enhance antitumor immune responses by increasing the recruitment of CD8 + T cells, CD56 + T cells, gd T cells, and NK cells. IFN-g secreted by these lymphocytes, as well as pDC-derived IFN-a, could also induce the secretion of CXCR3 ligands by tissue-resident cells, thereby forming a positive inflammatory feedback that promotes immune cell infiltration in the inflamed tumor microenvironment (Groom and Luster, 2011) . pDC-released IFN-a also enhances the cytolytic activity of the immune effector cells present. Tumor cell lysis by CD8 + T cells, NK cells, CD56 + T cells, and gd T cells might serve to release more tumor-associated antigen and make the dense lesion more accessible for infiltration by other immune cells. This strategy is supported by murine studies in which CpG-activated pDCs were injected intratumorally in melanoma or breast cancer Wu et al., 2017) . The injected pDCs recruited NK cells and CD8 + T cells into the tumor sites and enhanced their cytotoxicity, ultimately leading to a regression of both injected tumors as well as distant tumors. Interestingly, conventional DCs were responsible for T cell cross priming in the melanoma model , highlighting the potential benefit of using both pDCs and cDC2s in cancer vaccinations. How the potential synergy between pDCs and cDC2s is optimally exploited with regard to their mode of injection is currently not known. One option could be injecting cDC2s in the lymph node, where they can prime T cells, and pDCs in the tumor lesion, where they can recruit the activated T cells and enhance their cytolytic activity. Alternatively, the optimal combination of DC subsets could be achieved by co-injection at the same site. This matter should be addressed in future studies.
In summary, our study reveals the chemoattractive properties of DC vaccines utilizing primary DC subsets. We show that human pDCs and cDC2s secrete a distinct set of chemokines and attract discrete types of immune effector cells. Our results suggest that combining pDCs and cDC2s may unite the preferred chemoattractive properties of pDCs with the superior T cell priming properties of cDC2s, thereby possibly enhancing vaccine efficacy. Overall, our results highlight the potential of primary DC subsets for use in cancer vaccines.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human studies Patient material used in this study was acquired after informed consent and according to institutional guidelines. DTH skin biopsies from three stage IV melanoma patients who received FSME-pDC vaccination (study VI-A; Tel et al., 2013) and three stage IV melanoma patients who received GM-CSF-cDC2 vaccination (study VI-B; Schreibelt et al., 2016) were used for multiplex IHC staining. From the FSME-pDC trial, patients with long overall survival (> 20 months) were selected. From the GM-CSF-cDC2 trial, patients with the longest progression-free survival were selected. Patient characteristics are shown in Table 1 . Regardless of the number of vaccination cycles a patient received, only biopsies taken after the first cycle (i.e., third vaccination) were used in this study.
For flow cytometric analysis of DTH-derived cultures, 148 freshly isolated DTH biopsies of 48 stage III melanoma patients enrolled in an adjuvant DC vaccination study (Clinicaltrials.gov identifier: NCT02993315) were used. Analyzed patients received vaccination and DTH injection with combined antigen-loaded, pRNA-stimulated pDCs and cDC2s.
Primary cell cultures
Human DCs and naive CD4 + T cells were isolated from buffy coats of healthy individuals (Sanquin) after informed consent and according to institutional guidelines; age/sex information of blood donors was not available, as buffy coats were randomized. First, PBMCs were isolated by means of density centrifugation using Lymphoprep (Axis-Shield PoC AS). After depleting PBMCs of CD14 + cells with anti-CD14-conjugated microbeads (Miltenyi Biotec), cDC2s were purified by positive selection with a CD1c + DC isolation kit (Miltenyi Biotec). pDCs were purified by positive selection with a pDC isolation kit (Miltenyi Biotec), using PBMCs depleted of monocytes via anti-CD14-conjugated microbeads or adherence to plastic culture flasks. DC purity was up to 99% as assessed by flow cytometry with double staining for CD1c/CD11c for cDC2s and BDCA2/CD123 for pDCs. Naive CD4 + T cells were isolated from PBMCs with a naive CD4 + T cell isolation kit (Miltenyi Biotec). Cells were cultured in X-VIVO-15 medium (Lonza) supplemented with 2% human serum (Sanquin). pDCs and cDC2s were cultured either separately or together in a 96-well round-bottom plate at 1x10 6 cells/mL, and incubated overnight at 37 C, 5% CO 2 . For co-cultures of pDCs and cDC2s, a 1:1 ratio and a total DC concentration of 1x10 6 cells/mL was used. pDCs were stimulated with 5% FSME (Baxter AG) or 15 mg/mL pRNA, while cDC2s were stimulated with 800 U/mL GM-CSF (CellGenix) or 15 mg/mL pRNA. 10 ng/mL IL-3 (CellGenix) was added to all pDC-containing cultures as a survival factor. pRNA was prepared by diluting protamine (protaminehydrochloride MPH 5000 IE/ml; Meda Pharma BV) to 0.5 mg/mL in RNase-free water and mixing it 2:1 with 2-kbp-long single-stranded mRNA (coding for gp100). After extensive mixing, the mix was incubated for 5-10 minutes at room temperature (RT) before being added to the cell cultures. Th1 and Th2 cells were obtained from naive CD4 + T cells using a Th1 Cell Differentiation Kit and Th2 Cell Differentiation Kit (R&D systems), respectively, following manufacturer's instructions. Th17 cells were obtained by culturing naive CD4 + T cells for one week at 37 C, 5% CO 2 with 1000 IU/mL IL-2, 10 ng/mL of IL-1b, IL-6 and IL-23 (all PeproTech) and 20 ng/mL IL-21 (Miltenyi Biotec) in 96-well plates coated with 7 mL of 10 mg/mL anti-CD3 (clone OKT3) and 1 mg/mL anti-CD28 (clone 37.5; both Thermo Fisher) per well.
METHOD DETAILS
Gene expression analysis
We analyzed chemokine expression from RNA-seq data of human primary DCs deposited at the Gene Expression Omnibus (GEO; accession number: GSE89442) (Mathan et al., 2017) . We selected the chemokine genes for which the highest expression across samples was > 20 CPM. Logarithmically transformed CPM values were visualized by heatmap using the Morpheus software (Broad institute, Cambridge, MA; https://software.broadinstitute.org/morpheus). Hierarchical clustering on chemokine genes was performed using one minus Pearson correlation as distance metric.
Chemokine measurements
Concentrations of CXCL2, CXCL5, CXCL8, CXCL10, CCL4 and CCL22 in supernatants of DCs cultured overnight were measured using a Milliplex Human Chemokine Panel kit (Merck Millipore) according to manufacturer's instructions. Data were acquired using the Biorad Luminex 100 system.
Transwell migration assay
In vitro migration assays were performed using 24-well transwell plates with 5 mm pore size polycarbonate membrane (Corning Inc.). DCs were cultured as indicated. After 18 hours of culture, supernatants were harvested and transferred to the lower compartment of the transwell plate and diluted three times with medium to a total volume of 600 mL. As a negative control, medium without DC-derived supernatant was used. 1x10 6 PBMCs were seeded in 100 mL volume in the upper compartment. The plate was incubated for 3 hours at 37 C, 5% CO 2 to allow the cells to migrate. Migrated cells were collected from the lower compartment and stained with the following antibodies: anti-CD3-BV421, anti-TCRgd-FITC, anti-CD56-PE, anti-CD4-APC-Cy7 (all BD Biosciences), anti-CD14-PerCP-Cy5.5, anti-CD8-PE-Cy7 (both Biolegend), anti-CD45-VioGreen (Miltenyi Biotec) and anti-CD20-APC (Thermo Fisher). Cells were quantified on a MACS Quant flow cytometer (Miltenyi Biotec). Migration was calculated in fold increase as [number of migrated cells in condition] / [number of migrated cells in control]. For T helper cell migration, and PBMC migration in which CXCR3 was blocked, 96-well transwell plates with 5 mm pore size polycarbonate membrane (Corning Inc.) were used instead. In this case, 0.5x10 6 cells were seeded in 100 mL volume in the upper compartment and supernatants from DC cultures in the lower compartment were diluted two times with medium. For the CXCR3 blocking experiment, PBMCs were first pre-incubated with 0.5 mg/mL of antihuman CXCR3 antibody (R&D systems) for 1 hour at 37 C, 5% CO 2 , before use in migration assays as indicated.
Multiplex IHC panel
Tissue imaging and analysis Slides were scanned with the Vectra Automated Quantitative Pathology Imaging System (Vectra 3.0.5; PerkinElmer). Multispectral images were unmixed by the inForm Advanced Image Analysis software (inForm 2.4.1; PerkinElmer) with spectral libraries built from images of single stained tonsil cyrosections for each reagent. Unmixed multispectral images were loaded into Fiji (Schindelin et al., 2012) to draw regions of interest, thereby deselecting out-of-focus, collagen-rich regions. Subsequently, positivity thresholding for each fluorescent channel was performed. Threshold settings were kept constant for all other images belonging to the same tissue section. For each biopsy, the total number of positive pixels in a given fluorescent channel was divided by the average number of positive pixels in that channel per corresponding cell-type (calculated over 10 well-defined immune cells that were manually segmented) and by the total surface area in mm 2 of the biopsy. CD8 + T cells were defined as being CD8 + , CD8 -T cells were defined as being CD3 + CD8 -, NK cells were defined as being CD56 + CD3 -, CD56 + T cells were defined as being CD56 + CD3 + and gd T cells were defined as being TCRgd + CD3 + .
QUANTIFICATION AND STATISTICAL ANALYSES
All flow cytometry gating was done using FlowJo 10 software (FlowJo). Statistical significance for the transwell migration assays was determined by one-way ANOVA with Bonferroni correction using GraphPad Prism software version 7.0 (GraphPad Software Inc.). Statistical parameters are reported in the figure legends. Statistical significance is indicated with asterisks (ns, non-significant; *p < 0.05; **p < 0.01; ***p < 0.001). N-values indicated in the figure legends refer to biologically independent replicates.
DATA AND CODE AVAILABILITY
The accession number for the RNA sequencing data analyzed in this paper is GEO: GSE89442.
ADDITIONAL RESOURCES
IHC analysis was performed on DTH biopsies of melanoma patients enrolled in the clinical study with Clinical.gov identifier: NCT01690377. SKIL cultures were derived from DTH biopsies of melanoma patients enrolled in the clinical study with Clinicaltrials.gov identifier: NCT02993315. 
